Weight Loss & Metabolism

Small-molecule NNMT inhibitor studied for cellular energy expenditure and fat-cell metabolism.

1mg · 5mg · 10mg

Modified fragment of human growth hormone (176–191 region) studied for fat metabolism.

2mg · 5mg · 10mg · 20mg

Mitochondrial-derived peptide studied for exercise-mimetic metabolic signalling.

5mg · 10mg · 15mg · 20mg

Triple agonist of the GLP-1, GIP and glucagon receptors, studied for body-weight and metabolic outcomes.

5mg · 10mg · 20mg · 30mg · 50mg

GLP-1 receptor agonist widely studied for appetite regulation and glycaemic control.

1mg · 2mg · 5mg · 8mg · 10mg

Dual GIP/GLP-1 receptor agonist studied for weight management and insulin sensitivity.

5mg · 10mg · 15mg · 20mg · 30mg

Proapoptotic peptidomimetic studied for targeting the blood supply of adipose tissue.

2mg · 5mg · 10mg

AMPK activator studied in exercise-endurance and metabolic research.

50mg

Acetylated carnitine studied for mitochondrial energy metabolism and cognitive endpoints.

500mg

Long-acting amylin analogue studied for satiety signalling, often discussed alongside GLP-1 agonists.

5mg · 10mg

C-terminal fragment of growth hormone studied for lipolytic activity without GH-like effects on glucose.

2mg · 5mg

Amino-acid derivative central to fatty-acid transport into mitochondria.

500mg

Daily GLP-1 receptor agonist with a long research record in appetite and glucose studies.

5mg · 10mg

Dual GLP-1/glucagon receptor agonist in research for weight and lipid outcomes.

5mg · 10mg

ERR agonist described as an "exercise mimetic" in metabolic research.

5mg · 10mg

Glucagon/GLP-1 dual agonist studied for obesity and liver-fat endpoints.

5mg · 10mg